ISAR Summit Ploymer Free Everolimus Eluting Stent
World's 1st Polymer Free Everolimus Eluting Stent
Summit of innovative technology, offering a unique combination of Probucol and Everolimus.
ISAR SUMMIT uses a cobalt chromium platform, while the microporous surface, shellac resin and abluminal coating distinguishes it from other drug eluting stents.
Summit Of Innovative Technology
Drug Release Kinetics
*Biomaterials 2009 Feb; 30(4):632-7
Probucol: A Safer Alternative
- Probucol here mimics the role of a Polymer thus functioning as a drug carrier for the controlled release of Everolimus.
- Probucol seems to be a much safer alternative to polymers for drug release resulting in better anti-restenotic efficacy for ISAR SUMMIT*
*Data on file (IMTR Report 20210931)
Summit of Delivery Systems
Low Crossing Profile (0.89mm)
for enhanced deliverability.
Abluminal Coating
leading to faster endothelialisation.
Optimal Strut Thickness (68 µm)
for optimal radial strength.
Shellac Resin (Wax Free)
Acts like a smooth coat of drug matrix to prevent stent breakup during expansion.
Primary Endpoints
Composite safety endpoint of Target Lesion Failure (TLF) rate at 12 months post-index procedure
- Cardiac Death
- Target Vessel related Myocardial Infarction (TV-MI) and
- Clinically driven Target Lesion Revascularization (TLR)
Secondary Endpoints
Clinical endpoints measured at 30, 180 days and 1 year post index procedure
- Patient Oriented Composite Endpoint (PoCE) defined as the composite of all-cause death, any MI, any stroke and any revascularization
- Cardiac Death
- Any MI
- Definite/Probable Stent thrombosis as per Academic Research Consortium [ARC] definitions
